


PHARMACEUTICAL 2021

Zentalis Pharmaceuticals Inc. Rank 156 of 409





PHARMACEUTICAL 2021

Zentalis Pharmaceuticals Inc. Rank 156 of 409

The relative strengths and weaknesses of Zentalis Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zentalis Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 220% points. The greatest weakness of Zentalis Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is -57%, being 298% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	345,104
Cost of Goods Sold	0
Intangible Assets	3,736
Liabilities, Current	28,601
Liabilities, Non-Current	1,097
Other Assets	15,616
Other Compr. Net Income	743
Other Expenses	444
Other Liabilities	2,480
Other Net Income	683
Property and Equipment	1,099
Research and Development	84,901
Revenues	0
Selling, General and Administrative Expense	33,886

Output Variable	Value in 1000 USD
Assets	365,555
Liabilities	32,178
Expenses	119,231
Stockholders Equity	333,377
Net Income	-118,548
Comprehensive Net Income	-118,176
Economic Capital Ratio	-57%